Genmab A (GMAB) Depreciation and Depletion (2024 - 2026)

Genmab A has reported Depreciation and Depletion for 3 years, with the latest figure at $16.0 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation and Depletion rose 33.33% year-over-year to $16.0 million; the trailing twelve-month figure through Mar 2026 stood at $92.0 million (up 12.2% YoY), and the FY2025 full-year result was $55.0 million, up 12.24% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $16.0 million, down from $39.0 million in the prior quarter.
• The five-year high for Depreciation and Depletion was $39.0 million in Q3 2025, with the low at $11.0 million in Q1 2024.
• Historically, Depreciation and Depletion has averaged $23.1 million across 3 years, with a median of $23.0 million in 2024.
• Annual changes were most pronounced in 2025 — Depreciation and Depletion grew 8.33% — and 2026, when it jumped 33.33%.
• Genmab A's Depreciation and Depletion stood at $36.0 million in 2024, then climbed by 8.33% to $39.0 million in 2025, then slumped by 58.97% to $16.0 million in 2026.
• The last three Depreciation and Depletion figures came in at $16.0 million (Q1 2026), $39.0 million (Q3 2025), and $25.0 million (Q2 2025), per Business Quant data.